MeSH D006009 - glycogen storage disease type ii
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Sanofi | Alglucosidase alfa | Lumizyme |  | 2010-05-24 |  |  |
| Alglucosidase alfa | Myozyme |  | 2006-04-28 |  |  | |
| Avalglucosidase alfa | Nexviadyme |  | 2022-06-24 |  |  | |
| Avalglucosidase alfa | Nexviazyme |  | 2021-08-06 |  |  | |
| Amicus Therapeutics | Cipaglucosidase alfa | Pombiliti |  | 2023-03-20 |  |  |
| Miglustat | Opfolda |  | 2023-06-26 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
39%9/23
Phase 2
83%5/6
Phase 3
62%8/13
Approved: 4Overall Success rate: 20%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use